Australia · Delayed Price · Currency is AUD Cogstate Earnings Call Transcripts
Fiscal Year 2026
-
Record sales contracts and strong clinical trial growth drove double-digit revenue and earnings increases, with significant expansion in mood, sleep, and neuro segments. Margins are expected to recover in H2, supported by a robust pipeline, technology investment, and a strong cash position.
Fiscal Year 2025
-
Record financial results were achieved with strong revenue and profit growth, driven by diversification into new CNS indications and strategic partnerships. The Board declared a dividend, renewed the employee equity plan, and outlined continued investment in technology and AI. All resolutions were supported by proxies and no major risks or headwinds were reported.
-
Record revenue and profit growth driven by clinical trials and software licensing, with strong margins and cash flow. Strategic Medidata partnership and AI product launches set the stage for further expansion in CNS and psychiatric indications.
-
A strategic partnership between Cogstate and Medidata is driving innovation in CNS clinical trials through integrated digital cognitive assessments, advanced AI, and operational excellence. The collaboration is expanding into rare diseases and psychiatry, with strong early pipeline growth and industry recognition.
-
Record half-year revenue and profit growth driven by clinical trials and efficiency gains, with strong margins and positive cash flow. Strategic partnerships and technology investments are expanding the pipeline, though future contracted revenue declined due to healthcare segment changes.
Fiscal Year 2024
-
Revenue grew 7% year-over-year, driven by clinical trials, with profit before tax more than doubling and strong margin improvements. The renegotiated Eisai agreement returned IP control, enabling new opportunities, while the share buyback was suspended to preserve capital for potential acquisitions.